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Acquired angioedema due to C1 inhibitor de.ciency (C1INH-AAE) is a rare and potentially fatal syndrome of bradykinin-mediated
angioedema characterized by episodes of angioedema without urticaria. It typically manifests with nonpitting edema of the skin and
edema in the gastrointestinal (GI) tract mucosa or upper airway. Edema of the upper airway and tongue may lead to life-threatening
asphyxiation. C1INH-AAE is typically under-diagnosed because of its rarity and its propensity to mimic more common abdominal
conditions and allergic reactions. In this article, we present the case of a 62-year-old male with a history of recently diagnosed chronic
lymphocytic leukemia (CLL) who presented to our hospital with recurrent abdominal pain, initially suspected to have Clostridium
di!cile colitis and diverticulitis. He received a .nal diagnosis of acquired angioedema due to C1 esterase inhibitor de.ciency due to
concomitant symptoms of lip swelling, cutaneous nonpitting edema of his lower extremities, and complement level de.ciencies. He
received acute treatment with C1 esterase replacement and icatibant andwasmaintained on C1 esterase infusions. He also underwent
chemotherapy for his underlying CLL and did not experience further recurrence of his angioedema.
1. Introduction
Acquired angioedema due to C1 esterase inhibitor de.ciency
(C1INH-AAE) is a rare and potentially fatal disorder caused
by acquired consumption of C1 esterase inhibitor. Studies
estimate a prevalence rate between 1 in 100,000 and 1 in
500,000 patients, although it may be higher as the condition
is commonly unrecognized [1]. It may manifest with non-
pitting edema of the skin, including the skin of the face, lips,
limbs, or genitals, abdominal pain secondary to edema of the
gastrointestinal mucosa, and severe life-threatening edema
of the upper airway and oral mucosa [2].
2. Case Presentation
A 62-year-old male with a two-month history of recurrent
hospital admissions for abdominal pain presented to the
emergency room with colicky, generalized abdominal pain.
He also reported new asymmetric swelling of his upper and
lower lips. He denied associated di:culty swallowing or
breathing. He had no previous history of angioedema, food
allergies, or new medications. He denied any fever, chills,
malaise, trauma, nausea, vomiting, diarrhea, constipation,
hematochezia or melena, weight loss, sick contacts, neu-
rological de.cits, or recent travel history. Of note, he had
never taken angiotensin-converting enzyme inhibitors
(ACEi) or angiotensin receptor blocker medications. He was
a former smoker and quit 14 years ago and reported only
occasional alcohol intake. He had no family history of
angioedema. )is was the third hospital admission for ab-
dominal pain episodes within six weeks, with prior episodes
spontaneously resolving within a few days.
Six weeks prior to current presentation, a computed
tomography (CT) scan of the abdomen for a prior bout of
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this illness revealed di>use small bowel thickening with mild
adjacent mesenteric fat stranding and a thickened, nodular
terminal ileum and cecum. He also had a positive Clos-
tridium di!cile stool toxin test. He was treated with met-
ronidazole for C. di!cile colitis although diarrhea was not
a prominent symptom. Two weeks prior to current pre-
sentation, he was admitted for recurrent abdominal pain for
which another CT was performed, and on this one, he was
found to have severe jejunal edema, new proctocolitis, and
several enlarged mesenteric and inguinal lymph nodes. )e
lymph nodes were biopsied and found to have CD5-positive
cells consistent with a new diagnosis of chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL), later
con.rmed by bone marrow biopsy. )e patient was again
treated for presumed C. di!cile colitis, due to another
positive stool toxin test, this time with oral vancomycin.
He also received a course of amoxicillin-clavulanate as CT
abdomen showed extensive diverticulosis and evidence of
sigmoid colitis, introducing the possibility of diverticulitis.
Evaluation during that admission included esophagogas-
troduodenoscopy (EGD) and push enteroscopy. Both were
unremarkable except for previously known Barrett’s
esophagus. Interestingly, he also had asymmetric left lower
limb cutaneous swelling and pain during that admission
that had an unrevealing workup including a negative
Doppler ultrasound.
During the current presentation, vital signs were normal
with oxygen saturation at 95% on room air. Physical ex-
amination revealed lungs that were clear to auscultation
without stridor. Symmetric upper and lower lip swelling
without hives was noted (Figure 1).)e central abdomen was
mildly tender to palpation two inches above the umbilicus
with no guarding or rebound. No edema was noted in the
lower extremities during this current admission. All other
systems examined were normal.
3. Investigations
Complete blood count revealed a white blood count of
4900/μL (normal: 4,800–10,800/μL), hemoglobin of 12.4
(normal: 14–17.5 g/dL), and platelets of 149,000 (normal:
130,000–400,000/μL). Lactic acid, sedimentation rate, C-reactive
protein, lipase, and liver function tests were normal. Considering
the bouts of unexplained bowel edema and swelling lips
without hives, a diagnostic workup for angioedema was pur-
sued. Functional C1 esterase inhibitor level was found to be 4%
(normal: >40%), along with C1 esterase inhibitor antigen of<3mg/dl (normal: 21–39mg/dl), C4 complement< 1.7mg/dl
(normal: 12–38mg/dl), and low normal C1q level of 113μg/ml
(normal: 109–242μg/ml). C3 complement level was normal at
88.6mg/dl (normal: 59–152mg/dl). C. di!cile stool toxin test
during this admission was negative. Stool samples were also
negative for Salmonella, Shigella, Escherichia coli, Cam-
pylobacter, Yersinia enterocolitica, Giardia, Vibrio, and
Aeromonas. CT abdomen and pelvis (Figure 2) showed
jejunal enteritis with progressive duodenitis and stable
abdominopelvic lymphadenopathy. A repeat C1q level
performed 6 months later was low at <50 μg/ml
(109–242 μg/ml).
4. Differential Diagnosis
Given the patient’s history of positive C. di!cile stool tests,
a diagnosis of C. di!cile colitis was initially assigned, al-
though repeat stool toxin assay was negative. Diverticulitis,
acute pancreatitis, peptic ulcer disease, acute cholecystitis,
and inIammatory bowel syndrome were excluded based on
clinical history, negative biochemical and stool tests, EGD,
and CT abdomen/pelvis results. Stool studies were negative
for bacterial or parasitic infection that could otherwise
explain the CT scan .ndings. Viral gastroenteritis was
considered although patient denied any nausea, vomiting, or
diarrhea, and symptoms appeared to be recurrent.
Since nonspeci.c abdominal pain was accompanied with
symptoms of lip swelling and recent cutaneous swelling in
his lower extremities, a suspicion was formed of angioe-
dema. Allergic angioedema was excluded as the patient
denied urticaria and exposure to precipitating agents and
had abnormal complement levels in his serum. Similarly, the
presence of low C1-INH levels [3] and the absence of ACEi
use excluded ACEi-induced angioedema. Hereditary
angioedema (HAE) was unlikely because our patient denied
a family history of angioedema and experienced onset of
symptoms in his 6th decade, as opposed to before the 2nd
decade which is more typical of HAE [4].
5. Treatment
Patient was urgently administered intravenous methylpred-
nisolone 125mg and benadryl. Once a diagnosis of acquired
C1 esterase de.ciency was made, he received C1 esterase re-
placement and icatibant (a bradykinin B2 receptor antagonist).
He was subsequently maintained on C1 esterase replacement
therapy and given rescue injections of icatibant for acute
exacerbations. He also received outpatient chemotherapy for
his CLL/SLL with six cycles of rituximab, cyclophosphamide,
Figure 1: Patient with symmetric lip swelling of upper and lower lips.
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vincristine, and prednisone (R-CVP). He had no further ep-
isodes of abdominal pain, lip swelling, or lower extremity
swelling. Interval imaging with CT abdomen showed resolu-
tion of jejunitis and duodenitis (Figure 2).
6. Discussion
Approximately half of patients with C1INH-AAE may have
upper airway edema, and consequently death from asphyx-
iation or anoxic brain injury can occur in up to 30% of
patients [3, 5, 6]. However, more benign and nonspeci.c
presentations of GI angioedema and cutaneous edemamay be
the only manifesting symptoms. GI symptoms of angioedema
include nonspeci.c colicky abdominal pain, vomiting, di-
arrhea, and abdominal distension [2], which can be mistaken
for common abdominal conditions such as gastroenteritis and
diverticulitis. Cutaneous edema may manifest as nonpitting
edema of the skin, usually a>ecting the face but may also
involve the lower extremities, mimicking allergic reactions
and thrombophlebitis.
Because the diagnosis is extremely uncommon and its
symptoms are protean, there is frequently a delay in diagnosis.
A retrospective nationwide study in France found a median
delay in diagnosis of 10 months [3], whereas a national audit in
the United Kingdom showed a diagnostic delay of 5 years [7].
Our patient was diagnosed within only 2 months of symptom
onset, but after three hospital admissions and incorrect di-
agnoses of C. di!cile colitis and diverticulitis.
)e key pathologic abnormality in C1INH-AAE is the
acquired de.ciency of C1-inhibitor enzyme (C1-INH). A
major function of C1-INH is the inhibition of kallikrein, which
is a protease that cleaves kininogen and releases bradykinin [8].
Consequently, in C1-INH de.ciency, the absence of inhibition
of kallikrein leads to increased bradykinin levels, which then
facilitate vasodilation and increased tissue permeability,
resulting in angioedema Iares [8]. C1-INH de.ciency in
acquired angioedema (AAE) may be caused by excessive
consumption due to hyperactivation of the classic complement
pathways associated with underlying lymphoproliferative
diseases or by autoantibodies (autoimmune mediated).
Both lymphoproliferative disorders and autoantibodies
frequently coexist in the same patients and one may lead to
the other [9–11]. Our patient did not have antibodies tested,
but he did have CLL (a lymphoproliferative disease).
Laboratory .ndings include low C1-INH activity, low C3
and C4 levels, and autoantibodies to C1-INH in up to 70% of
patients with AAE [12, 13]. C1q level is typically low in up to
70% of patients, although itmay be normal in early stages of the
disease [14]. Our patient had lowC1-INH activity, lowC1-INH
level, low C4 complement, and an initially low-normal level of
C1q but low repeat C1q levels six months after diagnosis.
Most patients aMicted with C1INH-AAE also have
concomitant lymphoproliferative and autoimmune disor-
ders [15]. In one review that included 136 cases of acquired
C1 inhibitor de.ciency, lymphatic malignancies were
identi.ed in 35%, MGUS in 32%, autoimmune diseases in
8%, with adenocarcinoma, and other malignancies identi.ed
in 6% [15]. Lymphoproliferative disorders and B-cell ma-
lignancies are the most commonly associated conditions
[10, 16], especially splenic marginal zone lymphomas [17].
Associated autoimmune disorders include systemic lupus
erythematosus, cryoglobulinemia, and autoimmune hemo-
lytic anemia [18, 19]. Interestingly, there have also been
reports of association with Helicobacter pylori [20]. In our
case, the patient had been recently diagnosed with CLL,
a non-Hodgkin’s lymphoma with known association with
C1INH-AAE [13, 21–23].
Primary pharmacologic treatment for acute C1INH-
AAE includes C1 esterase inhibitor concentrate from hu-
man plasma or recombinant C1 inhibitor concentrate,
icatibant (a synthetic bradykinin B2 receptor antagonist),
and/or ecallantide (a kallikrein inhibitor). )e most widely
used therapy is C1 esterase inhibitor concentrate, although
resistance to this treatment over time, necessitating higher
doses to control symptoms, has been reported [10].
Importantly, unlike more common causes of angioe-
dema including allergic and drug-induced angioedema,
acute presentations of C1INH-AAE typically do not respond
(a) (b)
Figure 2: CT abdomen .ndings before and after treatment. (a) Before treatment, the patient was noted to have jejunal enteritis, which is
indicated by the target sign (red arrow). (b) After treatment, the patient had resolution of jejunitis (blue arrow).
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to corticosteroids, antihistamine, or epinephrine [24].
Prophylactic treatment to prevent recurrent symptoms of
C1INH-AAE includes C1 esterase inhibitor concentrate ad-
ministered every 3-4 days, attenuated androgens (i.e., danazol
and stanozolol) and anti.brinolytic agents [17, 25]. Our index
patient received C1 esterase inhibitor concentrate and icatibant
twice weekly prophylaxis with C1 esterase inhibitor concen-
trate. He experienced resolution of his symptoms following
initiation of that therapy and treatment of his lymphoma with
chemotherapy. Other case reports have documented similar
improvement in angioedema symptoms following treatment
of lymphoma [26].
Physicians caring for patients with unexplained ab-
dominal pain especially with concomitant skin, lip, or airway
swelling should consider angioedema as a possibility and
should check laboratory testing for con.rmation.
7. Teaching Points
(1) Wider appreciation of the possibility of C1INH-AAE
in refractory recurrent abdominal pain, particularly
in patients with lymphoproliferative disorders, could
lead to proper and timely medical therapy and avert
fatal respiratory complications from laryngeal and
upper airway edema.
(2) Abdominal symptoms in C1INH-AAE may mimic
gastroenteritis and diverticulitis, whereas nonpitting
cutaneous edema may be mistaken for allergic re-
actions and thrombophlebitis.
(3) Unlike more common causes of angioedema including
allergic and drug-induced angioedema, acute pre-
sentations of angioedema secondary to C1 esterase
de.ciency typically do not respond to corticosteroids,
antihistamine, or epinephrine and necessitate treat-
ment with C1 inhibitor replacement therapy, icati-
bant, ecallantide, or fresh frozen plasma.
(4) If an underlying associated disease is identi.ed in
a patient with C1INH-AAE, including lymphoproli-
ferative malignancy or autoimmune disease, treatment
of the underlying disease may lead to symptomatic
improvement of C1INH-AAE.
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